No products in the cart.
Pre-made Daxdilimab benchmark antibody ( Whole mAb, anti-LILRA4/ILT7 therapeutic antibody, Anti-CD85g Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-135
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19. and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
| Products Name (INN Index) | Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody |
|---|---|
| INN Name | Daxdilimab |
| Target | LILRA4 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Viela Bio |
| Conditions Approved | NA |
| Conditions Active | Cutaneous lupus erythematosus,Dermatomyositis,Polymyositis,Sjogren's syndrome,Systemic lupus erythematosus,Systemic scleroderma,Acute lung injury |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LILRA4/ILT7 |
| Package |
Previous slide
Next slide
